Georgia's Online Cancer Information Center

Find A Clinical Trial

A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

Cancer Type
Bladder Cancer
Kidney Cancer
Unknown Primary
Ureter Cancer
Urethral Cancer
Trial Phase
Phase I
Phase II
18 Years and older, Male and Female
Study Type
Protocol IDs
SGN22E-002 (primary)
Study Sponsor
Astellas Pharma Global Development, Inc.


This study will test an experimental drug (enfortumab vedotin) alone and with different
combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI)
that is used to treat patients with cancer of the urinary system (urothelial cancer). This
type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra. Some parts of
the study will look at locally advanced or metastatic urothelial cancer (la/mUC), which means
the cancer has spread to nearby tissues or to other areas of the body. Other parts of the
study will look at muscle-invasive bladder cancer (MIBC), which is cancer at an earlier stage
that has spread into the muscle wall of the bladder. This study will look at the side effects
of enfortumab vedotin alone and with other anticancer therapies. A side effect is a response
to a drug that is not part of the treatment effect. This study will also test if the cancer
shrinks with the different treatment combinations.


This study will examine the safety and anticancer activity of enfortumab vedotin (EV) given
intravenously as monotherapy and in combination with other anticancer therapies as first line
(1L) and second line (2L) treatment for patients with urothelial cancer. The primary goal of
the study is to determine the safety, tolerability, and efficacy of enfortumab vedotin alone
and in combination with pembrolizumab and/or chemotherapy. The study will be conducted in
multiple parts:

Locally advanced or metastatic urothelial cancer:

- Dose escalation

- Expansion

- Part 1: Cohorts A and Optional B

- Part 2: Cohorts D, E, and Optional F

- Part 3: Cohort G.

- Randomized Cohort K

- EV Monotherapy Arm

- EV Combination Arm

Muscle invasive bladder cancer:

- Cohort H

- Optional Cohort J

- Cohort L


  1. Locally advanced or metastatic urothelial cancer (la/mUC) - Cohorts A, B, D, E, F, G and K.
  2. Histologically documented la/mUC, including squamous differentiation or mixed cell types.
  3. An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1 or 2: Participants with ECOG performance status of 2 must meet the following additional criteria: hemoglobin =10 g/dL, GFR =50 mL/min, may not have NYHA Class III heart failure.
  4. Eligible for pembrolizumab (Dose-escalation cohorts, Cohorts A, B, G and K Combination Arm).
  5. Dose-escalation cohorts: Ineligible for first-line cisplatin-based chemotherapy and no prior treatment for la/mUC, or have disease progression following at least 1 platinum-containing treatment.
  6. Cohort A: Ineligible for cisplatin-based chemotherapy and no prior treatment for la/mUC. No prior adjuvant/neoadjuvant platinum-based therapy in at least 12 months.
  7. Cohort B: Must have disease progression during/following treatment with at least 1 platinum-containing regimen for la/mUC or disease recurrence.
  8. Cohort D: Eligible for cisplatin-based chemotherapy and no prior treatment for la/mUC. No prior adjuvant/neoadjuvant platinum-based therapy in at least 12 months.
  9. Cohort E: Ineligible for cisplatin-based chemotherapy, eligible for carboplatin, and no prior treatment for la/mUC. No prior adjuvant/neoadjuvant platinum-based therapy in at least 12 months.
  10. Cohort F: Ineligible for platinum-based chemotherapy, or disease progression during/following at least 1 prior treatment for la/mUC. Eligible for gemcitabine.
  11. Cohort G: Eligible for platinum-based chemotherapy (either cisplatin or carboplatin) and no prior treatment for la/mUC. No prior adjuvant/neoadjuvant platinum-based therapy in at least 12 months.
  12. Cohort K: Ineligible for cisplatin-based chemotherapy due to at least 1 of the following: Glomerular filtration rate (GFR) <60 mL/min and =30 mL/min, ECOG performance status of 2, NCI CTCAE Version 4.03 Grade =2 hearing loss, New York Heart Association (NYHA) Class III heart failure. No prior systemic treatment for locally advanced or metastatic disease. No adjuvant/neoadjuvant platinum-based therapy within 12 months prior to randomization.
  13. Muscle Invasive Bladder Cancer (MIBC)- Cohorts H, J and L.
  14. Histologically confirmed MIBC with predominant >50% urothelial histology: Cohorts H and J: Clinical stage cT2-T4aN0M0; Cohort L: Clinical stage cT2-T4aN0M0 or cT1-T4aN1M0: Participants with pT1 disease are eligible only if they have N1 disease on imaging. Mixed cell types are eligible if urothelial cancer is predominant (>50%); Participants with plasmacytoid and/or neuroendocrine tumors are ineligible regardless of component percentage. Urothelial tumors not originating in the bladder (eg, upper tract tumors, urethral tumors) are ineligible.
  15. Must be cisplatin-ineligible.
  16. Cohort-specific eligibility: Cohort J, H, and L: No prior systemic treatment, chemoradiation, or radiation therapy for MIBC. May have received prior intravesical Bacillus Calmette-Guerin (BCG) or intravesical chemotherapy for non-MIBC; Cohort J: Eligible for pembrolizumab.
  17. ECOG performance status of 0, 1, or 2.
  18. Anticipated life expectancy of =3 months.
  19. Tumor samples with an associated pathology report from the diagnostic transurethral resection of a bladder tumor done 90 days prior to the first dose of study treatment must be available prior to enrollment and determined to be sufficient for pathology review and biomarker analysis.
  20. Participants must be deemed eligible for RC+PLND.

Treatment Sites in Georgia

Piedmont Cancer Institute

1800 Howell Mill Road
Atlanta, GA 30318

Winship Cancer Institute of Emory University

1365 Clifton Road NE
Building C
Atlanta, GA 30322

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Georgia CORE


Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.